Dallas, TX -- (SBWIRE) -- 12/08/2014 -- The H5N1 Infection (Avian Influenza) – Pipeline Review, H2 2014 therapeutic industry research report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. Complete Report available @ http://www.rnrmarketresearch.com/h5n1-infection-avian-influenza-pipeline-review-h2-2014-market-report.html.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of H5N1 Infection (Avian Influenza) – Pipeline Review, H2 2014 covers: a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza); reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=248263 . (This is a premium report priced at US$2000 for a single user License.)

Companies discussed in this research include Akshaya Bio Inc., AlphaVax, Inc., Antigen Express, Inc., Aprogen, Inc., AstraZeneca PLC, BioDiem Ltd, CEL-SCI Corporation, Cocrystal Pharma, Inc., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., Gemmus Pharma Inc., GlaxoSmithKline plc, Green Cross Corporation, Hemispherx Biopharma, Inc., iBio, Inc., Immunovaccine, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Kineta, Inc., MacroGenics, Inc., Medicago Inc., Medigen Biotechnology Corporation, MedImmune, LLC, Microgen Scientific Industrial Company for Immunobiological Medicines, Myelo Therapeutics GmbH, NanoBio Corporation, Nanotherapeutics, Inc., NanoViricides, Inc., Novartis AG, OPKO Health, Inc., PaxVax
Protein Sciences Corporation, REPLICor Inc., SIGA Technologies, Inc., Sirnaomics, Inc., Takeda Pharmaceutical Company Limited, TechnoVax, Inc., Vaxart, Inc., Vaxin, Inc., VaxInnate Corporation, Vivaldi Biosciences Inc.

The clinical trial report "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014? provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Complete Report available @ http://www.rnrmarketresearch.com/h5n1-infection-avian-influenza-global-clinical-trials-review-h2-2014-market-report.html .

Scope of H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014 covers: Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each; Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type; Listings of discontinued trials (suspended, withdrawn and terminated). Order a purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=248716 . (This is a premium report priced at US$2500 for a single user License.)

Reasons to buy H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014 research report:
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Infectious Diseases Therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics.